(Bloomberg) — U.S. stock-index futures rose on Tuesday in Asia as some investors deemed that Monday’s equity rout brought prices to attractive levels.

S&P 500 Index futures contracts expiring in March rose 0.9{c34e2c9cd63a11c97fab811dbaaefe0cfbb1edd2527888e1a44d36f3491ee811} as of 11:31 a.m. in Tokyo, while contracts climbed 0.8{c34e2c9cd63a11c97fab811dbaaefe0cfbb1edd2527888e1a44d36f3491ee811} for the Dow Jones Industrial Average and advanced 1.2{c34e2c9cd63a11c97fab811dbaaefe0cfbb1edd2527888e1a44d36f3491ee811} for the Nasdaq 100.

Overnight, all three main U.S. stock benchmarks fell more than 3{c34e2c9cd63a11c97fab811dbaaefe0cfbb1edd2527888e1a44d36f3491ee811} amid growing concerns that the novel coronavirus is spreading more widely outside China. The S&P 500 dropped the most since February 2018 for the third consecutive day, its longest losing streak since December. U.S. stocks have lost about $1 trillion in value on Monday. Japan’s stock market also fell about 3{c34e2c9cd63a11c97fab811dbaaefe0cfbb1edd2527888e1a44d36f3491ee811} Tuesday morning.

“U.S. futures are going up a little on expectations dip buyers might emerge,” said Nader Naeimi, the head of dynamic markets at AMP Capital Investors Ltd. in Sydney. “There is also news out of Japan about possible treatment of coronavirus.”

Japanese newspaper Yomiuri Shimbun reported over the weekend that the government plans to recommend FujiFilm Holdings Corp.’s Avigan tablets for treating the coronavirus. Separately, U.S.-based Moderna Inc. said it sent the first batch of its vaccine to the National Institute of Allergy and Infectious Diseases to be used in the planned Phase 1 study in the U.S.

The Moderna report could have helped the rally in futures, according to Nick Twidale, general manager of IC Markets in Sydney. “It looks like a tentative first step in the right direction, but this will help markets,” he said.

For Saxo Capital Markets’s Eleanor Creagh, the S&P 500 could continue to see corrective moves, with price action “highly susceptible to virus related headlines as fears ebb and flow.”

”At present, we want to maintain optionality and hedge against these elevated tail risks,” said Creagh. “Namely, the impact of the coronavirus outbreak being far greater than is currently discounted across equity markets. This includes buying puts, remaining long gold, U.S. fixed income and volatility/volatility proxies that benefit from market turmoil.”

To contact the reporter on this story: Shoko Oda in Tokyo at soda13@bloomberg.net

To contact the editors responsible for this story: Lianting Tu at ltu4@bloomberg.net, Margo Towie

For more articles like this, please visit us at bloomberg.com

Subscribe now to stay ahead with the most trusted business news source.

©2020 Bloomberg L.P.